P342. The Preventive Potential of Bupropion on Aortic Aneurysm Progression: A Real-World Data Analysis
Presented During: POD Abstracts (Available for viewing in the exhibit hall for the duration of the meeting)
University of North Carolina at Chapel Hill
Chapel Hill, NC
United States - Contact Me
Native of Greece. Currently working as a PGY-1 resident physician at the University of North Carolina, Cardiothoracic surgery (Intergrated Thoracic Surgery program). Fully invested in pursuing an academic career in the field of cardiothoracic surgery.
Thursday, April 25, 2024: 5:38 PM - 7:00 PM
Sheraton Times Square
Room: Central Park
Description
Objective:
Bupropion is purported to effectively modulate two distinct pathways linked to the progression of aortic aneurysms. Notably, current literature indicates that bupropion demonstrates a capacity to inhibit the circulating levels of IL-6, MMP-2, and MMP-9, while concurrently increasing TIMP-1. This dual action aims to mitigate the advancement of aortic aneurysms. The principal objective of our study is to investigate the potential preventive impact of Bupropion on the progression of aortic aneurysms.
Methods:
Utilizing the Medicare Claims database (2007-2017), we identified a cohort of patients with major depressive disorder, seasonal affective disorder, and tobacco use-conditions for which Bupropion is FDA-approved. The comparative group included patients prescribed alternative medications (including SSRIs, SNRIs, mirtazapine, buspirone, nefazodone, trazodone, vilazodone, vortioxetine, varenicline, and nicotine) for the same diagnoses. Employing a comparative approach, we aimed to isolate the potential impact of Bupropion on aortic aneurysm progression. Throughout the study, patient aortic aneurysm development or interventions for repair were diligently tracked. The Kaplan-Meier method was employed for analysis.
Results:
In the database, we identified 916 patients treated with Bupropion and 46,052 treated with alternative medications. The median time to aneurysm diagnosis or repair was 29 months [IQR: 10, 60] in the Bupropion arm compared to 22 months [IQR: 8, 46] in the comparative arm (p<0.001).
Conclusions:
Our results generate the hypothesis that Bupropion might exhibit protective effects against aneurysm development and progression. This real-world data analysis aims to contribute valuable insights into the potential role of Bupropion in preventing the progression of aortic aneurysms, illuminating its broader cardiovascular implications beyond its well-established antidepressant properties.
Authors
Panagiotis Tasoudis (1), Christopher Agala (2), Kyle Alexander (3), John Blackwell (4), Elizabeth Collins (3), Yiwen Ding (3), Thomas Caranasos (5), John Ikonomidis (6), Adam Akerman (3)
Institutions
(1) University of North Carolina, Chapel Hill, NC, USA, (2) UNC Chapel Hill, Chapel Hill, NC, (3) University of North Carolina, Chapel Hill, NC, (4) UNC at Chapel Hill, Chapel Hill, NC, (5) N/A, Chapel Hill, United States, (6) UNC Medical Center, Chapel Hill, NC
Bupropion is purported to effectively modulate two distinct pathways linked to the progression of aortic aneurysms. Notably, current literature indicates that bupropion demonstrates a capacity to inhibit the circulating levels of IL-6, MMP-2, and MMP-9, while concurrently increasing TIMP-1. This dual action aims to mitigate the advancement of aortic aneurysms. The principal objective of our study is to investigate the potential preventive impact of Bupropion on the progression of aortic aneurysms.
Methods:
Utilizing the Medicare Claims database (2007-2017), we identified a cohort of patients with major depressive disorder, seasonal affective disorder, and tobacco use-conditions for which Bupropion is FDA-approved. The comparative group included patients prescribed alternative medications (including SSRIs, SNRIs, mirtazapine, buspirone, nefazodone, trazodone, vilazodone, vortioxetine, varenicline, and nicotine) for the same diagnoses. Employing a comparative approach, we aimed to isolate the potential impact of Bupropion on aortic aneurysm progression. Throughout the study, patient aortic aneurysm development or interventions for repair were diligently tracked. The Kaplan-Meier method was employed for analysis.
Results:
In the database, we identified 916 patients treated with Bupropion and 46,052 treated with alternative medications. The median time to aneurysm diagnosis or repair was 29 months [IQR: 10, 60] in the Bupropion arm compared to 22 months [IQR: 8, 46] in the comparative arm (p<0.001).
Conclusions:
Our results generate the hypothesis that Bupropion might exhibit protective effects against aneurysm development and progression. This real-world data analysis aims to contribute valuable insights into the potential role of Bupropion in preventing the progression of aortic aneurysms, illuminating its broader cardiovascular implications beyond its well-established antidepressant properties.
Authors
Panagiotis Tasoudis (1), Christopher Agala (2), Kyle Alexander (3), John Blackwell (4), Elizabeth Collins (3), Yiwen Ding (3), Thomas Caranasos (5), John Ikonomidis (6), Adam Akerman (3)
Institutions
(1) University of North Carolina, Chapel Hill, NC, USA, (2) UNC Chapel Hill, Chapel Hill, NC, (3) University of North Carolina, Chapel Hill, NC, (4) UNC at Chapel Hill, Chapel Hill, NC, (5) N/A, Chapel Hill, United States, (6) UNC Medical Center, Chapel Hill, NC
Presentation Duration
PODS will be on display in the exhibit hall for the duration of the meeting during exhibit hall hours. PODS will also be available for viewing on the meeting website. There is no formal presentation associated with your POD, but we encourage you to visit the PODS area during breaks to connect with those viewing.